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Background: Previous research suggests a possible link between insomnia and mortality, but findings are mixed
and well-controlled studies are lacking. The aim of the current study was to examine the effect of insomnia in
middle age on all-cause mortality.
Methods: Using a cohort design with 13-15 years follow-up, mortality registry data were linked to health information
obtained during 1997-99, as part of the community-based Hordaland Health Study (HUSK), in Western Norway. 6,236
participants aged 40–45 provided baseline information on self- reported insomnia using the Karolinska Sleep
Questionnaire Scale (defined according to the 5th edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-V), sociodemographic factors, health behaviors, shift/night-work, obstructive sleep apnea symptoms,
sleep duration, sleep medication use, anxiety, depression, as well as a range of somatic diagnoses and symptoms.
Height, weight and blood pressure were measured. Information on mortality was obtained from the Norwegian
Cause of Death Registry.
Results: Insomnia was reported by 5.6% (349/6236) at baseline and a significant predictor of all-cause-mortality
(hazard ratio [HR] = 2.74 [95% CI:1.75-4.30]). Adjusting for all confounders did not attenuate the effect (HR = 3.34
[95% CI:1.67-6.69]). Stratifying by gender, the effect was especially strong in men (HR = 4.72 [95% CI:2.48-9.03]);
but also significant in women (adjusted HR = 1.96 [95% CI:1.04-3.67]). The mortality risk among participants with
both insomnia and short sleep duration (<6.5 hours) was particularly high, whereas insomnia in combination
with normal/greater sleep duration was not associated with mortality.
Conclusions: Insomnia was associated with a three-fold risk of mortality over 13-15 years follow-up. The risk
appeared even higher in males or when insomnia was combined with short sleep duration, although such
unadjusted subgroup analyses should be interpreted with caution. Establishing prevention strategies and
low-threshold interventions should consequently be a prioritized task for public health policy.
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Numerous studies have investigated the association be-
tween sleep duration and mortality [1-3], but evidence
linking insomnia to mortality is less clear. Whereas some
studies have reported a significant association between
insomnia and mortality [4-8], others have not [9-16]. To
further complicate matters, some studies have even found
a protective effect of insomnia on mortality [17,18].* Correspondence: borge.sivertsen@fhi.no
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unless otherwise stated.The inconsistent results could reflect heterogeneous
study designs, inclusion of different covariates and different
operationalizations of insomnia. For example, a recent
study of older adults in Taiwan found that the association
between insomnia and mortality depended on the insomnia
definition [19]. Some studies have investigated insomnia
without accounting for sleep duration or use of hypnotic
medication, both factors themselves associated with
increased mortality, closely linked to insomnia and there-
fore potential confounders. For example, Finn et al. [4]
found a hazard ratio (HR) of insomnia for mortality of
2.1, but neither sleep duration nor use of hypnotics wereal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[7] found a significant effect of insomnia on mortality,
but without adjusting for use of hypnotic medication.
Another possible explanation for the inconsistent results
is that the association between insomnia and mortality is
constrained to certain groups. The Penn State Cohort
demonstrated that insomnia was associated with mortality
in men sleeping less than 6 hours, whereas no significant
effects of insomnia were found for men with longer sleep
duration, or for women [7]. Mallon et al. [6] also found
a gender specific effect, although the only other study
controlling for additional sleep covariates did not [5].
The ambiguous results in the existing literature con-
cerning the insomnia–mortality association therefore
require further examination, taking into account pos-
sible subgroup differences, important confounders and
correlates of insomnia such as hypnotic use and sleep
duration. In addition, insomnia should be defined
according to formal diagnostic criteria. Based on these
considerations, the aims of the current study were: 1)
to examine the independent effect of insomnia defined
according to the insomnia criteria found in the 5th edi-
tion of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-V) [20] on mortality risk after adjusting
for several confounders, including sleep covariates, in a
community-based sample from Norway (the Hordaland
Health Study), and 2) to examine whether the potential
effect of insomnia on mortality depended on gender and
sleep duration.
Methods
Study population and data material
The Hordaland Health Study (HUSK) comprises a joint
epidemiological research project carried out by the
Norwegian Health Screening Service in collaboration
with the University of Bergen. The base population for the
study reported herein included all 29,400 individuals in
the Hordaland County, Western Norway born 1953–57,
aged 40–45 years. Baseline data were collected by ques-
tionnaires and a brief clinical examination, which included
measurements of height, weight and blood pressure. A
total of 18,581 (8,598 men and 9,983 women) completed a
baseline questionnaire and met for the clinical examin-
ation, yielding a participation rate of 63% (57% for men
and 70% for women). At this visit, all participants were
randomly given one of two additional questionnaires.
Only one of these questionnaires included detailed
information on sleep. Of the 8,896 individuals receiving this
second questionnaire, 6,236 (70%) provided valid responses
on the sleep variables relevant for this study. The HUSK
study was conducted from 1997 to 1999, with the exception
of July, due to summer vacation. Previous findings from
both the HUSK study and a similar large population-based
study in Norway found no monthly or seasonal variationsin neither sleep duration, subjective sleep need, nor insom-
nia prevalence [21,22].
Measures
Outcome
The primary outcome of the present study was mortality
from any cause as registered by the Norwegian Cause of
Death Registry. This registry is kept by Statistics Norway
and includes information on cause of death for all deceased
persons registered as residents in Norway at the time of
death.
Exposure
The DSM-V criteria for insomnia include difficulty falling
asleep or difficulty maintaining sleep for a period of
3 months or more. In addition, it is a prerequisite that
the sleep disturbance impairs daily functioning [20]. In
this study, insomnia was assessed using the Karolinska
Sleep Questionnaire [23]. The measurement of the
insomnia diagnosis was based upon four items, each
rated along a five-point scale (“never”, “rarely (a few
times per year)”, “sometimes (a few times per month)”,
“mostly (several times a week)” or “always”). Subjects
were categorized as having insomnia if they reported
problems with sleep onset, sleep maintenance, or early
morning awakening (or a combination) “several times a
week” or “always” over the past three months, in addition
to reporting daytime tiredness/sleepiness mostly/several
days per week. Although the exposure was measured long
before the latest revision of the DSM, the questions used
were more in line with the updated DSM-V criteria than
previous DSM-versions. The Karolinska Sleep Question-
naire has been shown to have good psychometric properties
[24], and was recently validated against clinical diagnosis of
insomnia in a Norwegian sample [25].
To examine if there was a potential effect beyond the
diagnostic cut-off value (insomnia versus not insomnia),
we also used a continuous measure of insomnia as an in-
dependent variable. This variable was created by adding
the scores on the 3 items assessing nocturnal insomnia
symptoms (score ranging from 0-4: sleep onset problems,
sleep maintenance problems, or early morning awaken-
ings) as well as the single daytime tiredness/sleepiness
item. The sum score ranged from 0-16.
Other participant characteristics
Level of education was reported in four categories ranging
from less than seven years of schooling up to at least
4 years of higher education at college/university. We also
collected data on marital/cohabitant status (dichotomized
into living alone or with a partner), smoking (number of
daily smoked cigarettes) and weekly level of exercise: [1]
no or easy physical activity 1 hr/week, [2] moderate phy-
sical activity 1 to 2 hrs/week, or [3] hard physical activity
Sivertsen et al. BMC Public Health 2014, 14:720 Page 3 of 10
http://www.biomedcentral.com/1471-2458/14/720more than 2 hrs/week. Alcohol consumption was cate-
gorized according to weekly number of self-reported
alcohol units (none, 1-2 units/week, 3-4 units/week,
or ≥ 5 units/week). Body mass index (BMI) was calcu-
lated by dividing weight (kg) by squared height (m2).
The lifestyle behaviors and BMI were included as
confounders due to previous studies linking them both
to insomnia [26] and mortality [27].
Questions on somatic diagnoses were framed the fol-
lowing way: “Do you have or have you had (one or more
of the following)”: myocardial infarction, stroke, diabetes,
or angina. Endorsement of these alternatives were consi-
dered self-reported diagnoses positive, coded dichoto-
mously to indicate presence or not of that condition.
Subjects were also asked about the frequency of 17
common bodily symptoms related to different organ
systems in accordance with the 10th edition of the Inter-
national Classification of Disorders (ICD-10) Research
Criteria for F45 Somatoform Disorders [28] on a five
point (0-4) Likert scale labeled: “almost never, rarely,
sometimes, often and almost always”. The items were
summed and the composite score reflects “organ system
symptoms” that is used as a continuous variable, with
increasing levels reflecting higher symptom load.
Musculoskeletal pain was assessed by the following
introductory question: “Have you during the last year
experienced pain and/or stiffness in muscles or joints
lasting for at least three consecutive months”? If yes, the
participants were asked to indicate the location(s) from
the following list (“yes” or “no”): neck, shoulder, elbow,
hands/wrist, chest/abdomen, upper back, lower back,
hips, knees, ankles or feet. Based on the responses we
then constructed a dichotomous variable, where those
who reported pain from any of these locations where
defined as having musculoskeletal pain.
Symptoms of current non-vegetative anxiety and
depression symptoms were measured using the Hos-
pital Anxiety and Depression Scale (HADS) [29], a self-
report questionnaire comprising 14 items, each with a
four-point response alternatives. Seven items reflect an-
xiety symptoms (HADS-A) and seven reflect symptoms of
depression (HADS-D). In the analyses the HADS-scores
were used as continuous variables. The HADS has been
found to perform well in assessing severity of anxiety and
depression in both hospital settings (for which it was first
designed), but also in primary care patients and the
general population [30]. A cut-off score of 8 gives the best
balance between sensitivity and specificity at about 0.80
for depression according to DSM-III and IV, ICD-8 and 9
criteria, and is supported as a case-identifying symptom
level in general practice [31].
Symptoms of obstructive sleep apnea (OSA) were
estimated using three items from the Karolinska Sleep
Questionnaire [23]. These items were used to identifyindividuals at-risk for OSA based on their own or their
partner’s reports on “snoring” and “breathing cessation”
during sleep. In addition to the requirement of reporting
both of these core symptoms either “sometimes (several
times a month)”, “often (several times a week)” or “always”,
participants were only classified as having symptoms of
OSA if they also were “tired or sleepy at work or during
spare time”, “sometimes”, “often” or “always”. This opera-
tionalization has also been used in a previous study based
on the same data examining the effect of OSA on work dis-
ability [32]. A similar definition in line with the Hawaiian
Sleep Questionnaire (the Apnea Score) has previously been
shown to identify 100% of the cases with severe sleep apnea
(Apnea-Hypopnea Index [AHI] > 40) and 75% of all sleep
apnea cases with AHI > 5, and shown an overall predictive
accuracy of 88% for AHI > 10 [33].
Use of hypnotic medication was assessed in two ways.
First, participants were asked if they had used hypnotic
medication on a daily or nearly daily basis over the last
year, and for how many months they had used them. For
the current analyses, a continuous variable comprising
months of use was employed. Second, participants
answered an open-ended question were they provided the
name of all medications they took the day before baseline
assessment. These were coded according to the Anatomical
Therapeutic Chemical (ATC) classification system [34], and
for the current study all mediations in the ATC–subgroup
N05C (hypnotics and sedatives) were included (barbitu-
rates, aldehydes and derivatives, benzodiazepine derivatives,
piperidinedione derivatives, benzodiazepine related drugs,
melatonin receptor agonists, and other hypnotics and
sedatives).
Sleep duration was defined as time in bed (calculated
from self-reported bedtime and rise time) minus self-
reported sleep latency. For analyses purposes, sleep
duration was split into 5 groups based on percentiles,
according to the following cut-off points: 5.5 hours = 5th
percentile; 6.5 hours = 25th percentile; 7.5 hours = 75th
percentile, 8.5 hours = 95th percentile. We also dicho-
tomized sleep duration into “short sleepers” (less than
6.5 hours) and “normal/long sleepers” (6.5 hours or more).
Sleep duration was assessed separately for workdays and
weekends; in the present article we focus only on sleep
duration on workdays; as such sleep data are more
consistent [22].
Statistical analysis and models
STATA/SE 13.1 was used for all analyses. Independent
sample t-tests and χ2-tests were used to examine demo-
graphic and clinical differences between participants with
insomnia and good sleepers. Cox proportional hazards
models were computed to assess the effect of insomnia on
all-cause mortality, both crude and adjusting for each
covariate separately. The following variables were included
Sivertsen et al. BMC Public Health 2014, 14:720 Page 4 of 10
http://www.biomedcentral.com/1471-2458/14/720as potential confounders: age, gender, education, health
behaviors, body mass index, somatic diagnoses, somatic
symptoms, musculoskeletal pain, mental disorders, ob-
structive sleep apnea, sleep medication use, and sleep
duration (entered as a 5-class categorical variable). We
also tested for interactions between insomnia and sex,
and insomnia and sleep duration, by entering the product
of these variables in separate blocks. A final multivariate
model including all covariates was also employed. In
addition to using insomnia as a dichotomous variable, we
also tested the effect of the continuous total insomnia
score on mortality. Participants were followed from the
date of participation in HUSK (1997-1999) to their death
or end of follow-up (December 31, 2012), at which point
they were censored (range of follow-up: 13 to 15 years).
Results are presented as hazard ratios (HR) with 95
percent confidence intervals (95% CI). We evaluated the
proportional hazard assumption by inspecting the log
minus log plots stratified on the level for each covariate
and found no major deviation from a proportional hazard.
Although no detailed analyses on cause-specific deaths
were conducted due to the limited sample size, simple
cross-tabulations were examined. As a sensitivity analysis,
we repeated all analyses excluding participants who died
during the first two years of the follow-up. This was
done to reduce a possible bias if the measure of inso-
mnia was capturing a severe illness resulting in both sleep
disturbance and a high likelihood of imminent death. We
tested for multicollinearity by inspecting tolerance values
and Variance Inflation Factors (VIFs) using the ‘collin’
command in STATA, and all values were well within the
recommended limits [35]. Visual inspection of plots
showed no sign of a curvilinear association between
insomnia symptoms (continuous score) and mortality.
Missing values were handled using listwise deletion.
Ethics
The study protocol was approved by the Regional Commit-
tee for Medical Research Ethics of Western Norway and
approved by the Norwegian Data Inspectorate. Written
consent was obtained from all subjects included in
this study.
Results
Sample characteristics
Baseline demographic and clinical characteristics are pre-
sented in Table 1. The prevalence of insomnia was 5.6%.
Insomnia was more prevalent among women, current
smokers, persons with low education, and among those
with low physical activity. Insomnia was also positively
associated with BMI, symptoms of anxiety, depression
and OSA, self-reported angina and number of somatic
symptoms and musculoskeletal pain, as well as use of
sleep medication and short sleep duration. Insomniawas unrelated to alcohol consumption, blood pressure, and
to reported diabetes, myocardial infarction and stroke.The effect of insomnia on all-cause mortality
During the follow-up period from 1997-1999 through
2012, 160/6233 (2.6%) persons died, of which 93/3858
(2.4%) were female and 67/2377 (2.8%) were male. In the
crude analyses, insomnia was associated with an almost
three-fold increase in mortality (hazards ratio (HR) = 2.74;
95% CI: 1.75–4.30; Figure 1 and Table 2). Including the
confounders as adjustment variables, one at a time, only
slightly changed the effect estimates. In the fully adjusted
model, insomnia was even more strongly associated with
mortality than in the crude analysis (HR = 3.34; 95% CI:
1.67–6.69).
When stratifying the analyses by gender we found that
male insomniacs had almost 4 times higher risk of mor-
tality compared to male good sleepers (crude HR = 4.72;
95% CI: 2.48–9.03; Figure 2), whereas the corresponding
effect for women was HR = 1.96 (95% CI: 1.04–3.67). The
interaction between insomnia and gender was statistically
significant with a stronger effect of insomnia for males
compared to females (P = 0.050).
The mortality risk was higher in insomniacs sleeping
less than 6.5 hours (crude HR = 2.79; 95% CI: 1.26–6.17;
Figure 2) compared those sleeping 6.5 hours or more. The
association between insomnia with normal or greater
sleep duration and mortality was not significant (crude
HR = 1.78; 95% CI: 0.78–4.06). However the interaction
between insomnia and sleep duration was not statistically
significant (P = 0.44).
As a sensitivity analyses, we repeated the analyses after
excluding deaths occurring in the first 2 years of follow-up.
This resulted in 8 deaths being omitted, still the asso-
ciations remained practically identical: crude HR= 2.76
(95%CI: 1.74-4.38) and adj. HR = 3.29 (95% CI: 1.60–6.78).
We also repeated the analyses using the continuous
insomnia score as exposure variable. These analyses
showed that the crude HR was 1.08 (95% CI: 1.02-1.15),
equal to an 8.3% increase in mortality rate for every in-
creasing value of the insomnia score (range 0-16). The
fully adjusted HR was 1.10 (95% CI: 1.01-1.20), indicating
a 10.1% increase in mortality rate.Cause of death
Although the low numbers of deaths in the current
study prevented detailed analyses of cause of death,
crude analyses showed no clear pattern of specific
causes being more prevalent in the insomnia vs. the
non-insomnia group. The most common cause of
death among insomniacs was cancer (48%) followed by
CVD (9.5%), as was also the case in the non-insomnia
group.
Table 1 Baseline demographic and clinical characteristics
according to insomnia status in the Hordaland Health
Study, Norway, 1997-1999#
Characteristics No insomnia Insomnia P-Value
N, % 5887, 94.4% 349, 5.6%
Age§ 42.6 (1.5) 42.6 (1.5) .67
Women 61.3% 71.8% <.001
Education .014
Compulsory 16.9% 23.0%
High school 45.8% 42.2%
College/university 37.3% 34.9%
Number of daily smoked
cigarettes§
11.0 (6.7) 12.7 (7.1) <.001
Alcohol consumption† .77
0 units/week 8.3% 9.4%
1-2 units/week 32.6% 32.2%
3-4 units/week 31.5% 29.5%
≥ 5 units/week 27.6% 28.9%
Physical activity <.001
No or easy 13.5% 22.7%
Moderate 42.5% 38.8%
Heavy 44.0% 38.5%
Shift/night-work 24.2% 24.1% .98
Body-mass index (BMI)§ 25.2 (3.8) 25.6 (4.5) .030
Systolic blood pressure§ 126.3 (14.5) 125.9 (14.4) .64
Myocardial infarction 0.3% 0.3% .60
Angina 0.4% 1.4% .013
Stroke 0.2% 0.6% .22
Diabetes 0.8% 1.1% .36
Somatic symptoms§ 10.2 (7.1) 21.2 (9.1) <.001
Musculoskeletal pain 13.7% 43.4% <.001
Anxiety score§ 4.0 (2.9) 8.9 (3.9) <.001
Depression score § 2.7 (2.5) 6.3 (3.7) <.001
Obstructive sleep apnea symptoms 4.6% 14.7% <.001
Daily sleep medications use
(months)§
0.1 (2.0) 1.7 (5.8) <.001
Sleep medications (ATC-subgroup
N05C)
0.1% 5.2% <.001
Sleep duration <.001
< 5.5 hours 2.9% 13.5%
5.5-6.5 hours 15.3% 26.3%
6.5-7.5 hours 48.0% 36.5%
7.5-8.5 hours 28.8% 15.7%
> 8.5 hours 5.1% 8.0%
#Missing data were overall all low and ranged from 0% (age, gender, BMI,
systolic blood pressure) to 10.7% (sleep duration).
†1 unit equals approximately 12 g ethanol.
§Data presented as mean (SD).
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The aim of this study was to investigate the effect of
insomnia on mortality in a middle-age population, after
taking into account the effect on mortality of many pos-
sible confounders including sleep duration, use of sleep
medications and symptoms of OSA. In short, insomnia
increased the risk of death 3-fold in the fully adjusted
analyses. In exploratory analyses the effect of insomnia
was appeared especially strong for men, and among
insomniacs who also reported short sleep duration.
The link between sleep and mortality has been exten-
sively studied over the last decades. Whereas the evidence
of harmful effects of short and long sleep duration (see
[1-3] for review) and use of hypnotics [36] is ample, the
literature on any association between insomnia and mor-
tality has been much more inconsistent. An important
issue when studying any consequence of sleep, is to diffe-
rentiate between distinct types of sleep problems. For
example, although there is a significant overlap between
those who report insomnia and those with short sleep
duration [37], it is also important to distinguish between
these two groups. In addition to the diagnostic criteria of
difficulty falling asleep and maintaining asleep, associated
with daytime impairment or distress, a diagnosis of in-
somnia also requires that the sleep disturbance must
occur despite adequate opportunity and circumstances
for sleep [38]. As such, voluntary or enforced (e.g. post-
partum) sleep loss, characteristic for behaviorally induced
insufficient sleep syndrome, should not be misclassified as
insomnia, although such patients normally report sound
sleep [39]. The distinction between sleep deprivation and
insomnia is important when studying their respective con-
sequences. For example, whereas sleep deprivation con-
sistently has been linked to reduced neuropsychological
performance [40] although with marked intra-individual
variability, the effect of insomnia on this outcome is less
clear, and at best more subtle and qualitatively different
from sleep loss [41]. Furthermore, patients with advanced
or delayed sleep phase syndrome normally complain of
early morning awakening and sleep onset difficulties,
respectively, and it is not uncommon that studies
misattribute such symptoms to insomnia rather than to a
circadian rhythm sleep disorder [42].
We were able to identify 17 studies [4-19,43] investi-
gating the effect of insomnia on mortality, of which 5
studies found a harmful effect [4-8]. Among these five,
only two studies controlled for both sleep duration, use
of hypnotic medication and OSA, in addition to other
somatic and psychiatric (depression) confounders [5,6].
So far no study has investigated the relationship between
DSM-V based insomnia criteria and mortality. Our multi-
variable adjusted findings show that insomnia increased
the risk of mortality 3.3 times compared to good sleepers,
an effect somewhat larger than found by Hublin et al.
Figure 1 Kaplan-Meier survival curves by insomnia status (fully adjusted analyses) in the Hordaland Health Study (1997-1999).
Table 2 Crude and covariate-adjusted* hazard ratios of
mortality risk associated with insomnia, during 14 years
follow-up of the Hordaland Health Study (1997-1999)
Hazard
ratio
95% confidence
intervals
Adjustment variables:
Crude (insomnia only) 2.74 1.75 – 4.30
Age, gender and education 2.82 1.79 – 4.44
Health behaviorsa 2.59 1.75 – 4.30
Shift/night-work 2.97 1.87 - 4.72
Body mass index 2.71 1.73 – 4.26
Somatic diagnosisb 2.67 1.70 – 4.20
Somatic symptoms 2.74 1.67 – 4.54
Musculoskeletal pain 2.88 1.80 – 4.59
Mental disordersc 2.59 1.54 – 4.35
Obstructive sleep apnea symptoms 2.86 1.82 – 4.51
Sleep medications 2.94 1.84 – 4.70
Sleep duration 2.20 1.26 – 3.86
Fully adjusted analyses 3.34 1.67 – 6.69
*Covariates are adjusted for one by one. Fully adjusted analyses include
all covariates.
aSmoking, alcohol, and physical exercise.
bSystolic blood pressure, myocardial infarction, angina, stroke, diabetes.
cAnxiety and depression symptom load.
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analyses in the current study suggested that this associ-
ation was stronger in men: Male insomniacs were 4.7
times more likely to die than non-insomniac males in the
crude analyses, while a lower, but still significant effect
was observed for women (HR = 2.0). We also found a
possible, although not statistically significant, interaction
effect of insomnia and short sleep duration on mortality.
Participants reporting both insomnia and sleeping less
than 6.5 hours had 2.8 times higher risk of dying during
follow-up than non-insomniacs. A similar effect of the
deleterious combination of short sleep duration and
insomnia was also observed by Vgontzas et al.[7] in a
polysomnographic study of insomniacs.
The findings from the current study suggest that the
insomnia-mortality association may be confined to sub-
groups: males and short sleepers. This may be part of the
explanation why many previous studies have not found an
independent effect of insomnia on mortality. Inconsistent
operationalization of insomnia is another possible reason
for the mixed findings. In the current study, we used a
definition of insomnia, which resembles both The
Research Diagnostic Criteria (RDC) for insomnia [38]
as well as the DSM-V criteria [45]. A similar definition
was used in the Hublin et al. study in which a somewhat
smaller effect was observed. In contrast, some of the
studies failing to find an effect of insomnia have relied on
less-than-optimal definitions, often resorting to a single
item, to assess insomnia. However, both Lack et al. [12]
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Figure 2 Unadjusted hazard-ratios of mortality risk associated with insomnia, stratified by sex and sleep duration during 13-15
years follow-up of the Hordaland Health Study (1997-1999). Error bars represent 95% confidence intervals. Note that y-axis is on a
logarithmic scale.
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tions of insomnia, but nevertheless found no association
between insomnia and deaths. Thus, operationalization
issues may not explain all the observed discrepancies. To
sum up, although the literature on insomnia predicting
death is mixed, the current study clearly shows a strong
link between well-characterized insomnia and mortality
even after adjusting for confounders.
The big question is then: Why does insomnia predict
premature death? Individual covariates in the current
study only partly explained the association, and multiple
adjustment actually increased the hazard ratio. For ex-
ample, we found that adjusting for smoking, alcohol use
and physical exercise reduced the effect of insomnia on
mortality only to some extent (from HR= 2.7 to HR= 2.6).
To our surprise, adjusting for depression and somatic diag-
noses (hypertension, myocardial infarction, angina, stroke,
or diabetes) did not indicate that these comorbid conditions
are important pathways. However, the lack of mediation by
somatic diagnosis may relate to the study sample being
relatively young, and thereby healthier than older adults.
With cancer being by far the most common cause in this
middle age group many such somatic diagnoses and riskfactors would be unlikely to be a mediator. The gender dif-
ferences in the current study led us to speculate that there
might be certain occupational aspects linking insomnia to
mortality, but we found no evidence of insomnia being
linked to accidents in hazardous occupations [46], although
were limited by the limited number of cause specific
outcomes. As such, the question as to why insomnia
may increase the risk of death remains open to further
examination, especially in terms of exploring more
specific the causes of deaths.
There are important methodological considerations to
the present study that should be noted. First, the re-
striction of the sample to participants aged 40-45
limits the generalizability of the findings to other age
groups. Second, insomnia was assessed by self-report
rather than based on a clinical diagnosis. However, the
questionnaire used in our study, the Karolinska Sleep
Questionnaire, is relatively analogous to the criteria for
insomnia as specified by the DSM-V [20], and the preva-
lence found in the present study (5.6%) is identical to a
previous report using a stringent DSM-IV definition of in-
somnia [47], suggesting a reasonable estimate of insomnia
disorder prevalence in the current study. However, we
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problems commonly fluctuate over time, it would be
better to have repeated measurements over a long time
period in order to identify chronic insomniacs. An import-
ant addition to the DSM-IV and DSM-V from previous
versions was the inclusion of a clinical significance criterion
to almost half of all the categories (including insomnia),
which required that symptoms cause clinically significant
distress or impairment in social, occupational, or other
important areas of functioning. A similar impact on fam-
ily, social or occupational life is also required in the latest
ICD-10 criteria for insomnia. Still, the definition of insom-
nia in the current study operationalized the daytime cri-
terion through self-reported tiredness or sleepiness only,
and there are other domains of daily functioning that
could be affected beyond these items.
There are also other limitations of the present study
related to sleep measurement issues: First, the operatio-
nalization of OSA was based on a brief self-report ques-
tionnaire. Although the prevalence estimate found in the
present study (8.4%) is similar to that found in other epi-
demiological studies in similar age groups [48-52], the
use of self-reported symptoms to measure OSA remains
problematic because persons are often unaware of their
behavior during sleep. However, the Karolinska Sleep
Questionnaire is based on sleep problems also reported
by the person’s spouse or co-habitant and thus attempts
to improve the validity of reported symptoms. Another
source of confounding is that both the OSA and insomnia
operationalizations included the same item assessing
reduced daytime functioning (daytime/sleepiness). Second,
the measure of sleep duration did not include reports of
wake time after sleep onset (WASO). As such, there is a
risk that we may have overestimated sleep duration, espe-
cially in persons with maintenance and early morning
awakening insomnia. Third, self-reported use of sleep
medications was limited to daily or nearly daily basis over
the last year. This is a strict definition with individuals
using medication 3-4 times per week (and less frequently)
not being accounted for.
The list of possible confounding factors most likely did
not capture all possible confounding effects from chronic
somatic or psychiatric conditions, and there might be
other relevant risk factors for mortality not assessed in the
current study. Self-report instruments are prone to error
and residual confounding cannot therefore be ruled out.
Screening for psychiatric morbidity was limited to symp-
toms of anxiety and depression. In addition, some of the
confounders were operationalized in a rather crude way.
For example, the employed cut-off for alcohol consump-
tion was based on weekly instead of daily intake. This puts
some limitation on the adjustment for confounders con-
cerning the association between insomnia and mortality.
Also, the number of deaths was limited to 160, whichprevented us from conducting further sub-analyses, for
example on the interaction between insomnia and OSA
and use of hypnotic medication, and also precluded us
from investigation of the relationship between insomnia
and specific causes of death. The small number of deaths
in the insomnia group also represents a problem with
regards to statistical power. A related issue concerns the
long list of adjustment variables that were used in the re-
gression analyses. Given the modest sample size, it is not
unproblematic to include so many confounders, which
may distort some of the statistical findings. For example,
we cannot easily explain why the fully adjusted HRs in
several instances were larger than the unadjusted. For this
reason, we did not conduct fully adjusted analyses when
examining subgroups (interaction with gender and sleep
duration). Also, as the current study included measures of
both insomnia, sleep medications, sleep duration and
OSA, multicollinearity could have produced biased re-
sults, but testing for this in the current study showed
this not to be the case (with tolerance values larger than
0.61 and VIFs less than 1.63 for all predictor variables)
[53]. This issue was also pointed to by Hublin et al. [44]
emphasizing how difficult it is to fully separate risks of
insomnia from those of similar conditions and disor-
ders. Therefore, the findings, and especially those from
the fully adjusted analyses, should be interpreted with
caution and repeated by studies based on larger sam-
ples. Also, given the age in our study population, several
risk factors that were not present at baseline (obesity,
sleep apnea, diabetes, etc.) may have emerged later du-
ring the course of follow-up, which may have influenced
the outcome. Finally, the participation rate was not very
high (63%) and generalizations of the results must be
made with caution as both mortality rates [54] and
symptom levels [55] are higher among non-participants.
There are several strengths of this study that deserves
mention. First, the design included complete follow-up
through the nationwide Cause of Death Registry, made
possible through linkage using the personal identification
number unique to each Norwegian resident. Also, the
comprehensive list of confounders, including other sleep
variables, allowed investigation of the unique effect of
insomnia. In addition, the study had sufficient statistical
power to conduct sub-analyses of the interaction effects of
insomnia and gender and sleep duration.
Conclusion
In conclusion, insomnia was found to be a strong risk
factor for death among middle-aged adults over 13-15
years follow-up, even after adjusting for potential con-
founders, and the results suggest the risk is stronger in, if
not confined to, males and insomniacs with short sleep
duration. The number of deaths observed in this study
was low, and challenges statistical power, particularly in
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http://www.biomedcentral.com/1471-2458/14/720the multivariate models and subgroup analyses. As the
findings were stronger compared to those reported
elsewhere, they should be interpreted with caution and
repeated in larger samples where the rates of outcomes
are higher. Nevertheless, given the high prevalence of
insomnia in the general population and the range of
negative outcomes repeatedly linked with insomnia,
these results should, if nothing else, support public health
policy advances in prevention and low-threshold interven-
tions for insomnia.
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